Zealand Pharma Preps Pipeline For Catalyst-Filled 2020
Biotech’s CEO Hopes For Four US approvals In 2020
Executive Summary
Zealand Pharma’s recently installed CEO says it is building US operations to prepare for four potential approvals there in 2020, with commercial launches starting in 2021, its first ever.
You may also be interested in...
Novo Nordisk Targets Smart Insulin, Stem Cell-Therapies
Novo Nordisk’s CEO talks to Scrip about the promise of glucose-responsive insulin, stem cell therapy, and a diabetes landscape without Sanofi.
Ipsen’s Palovarotene Hit By FDA Clinical Hold
The US FDA has slapped a partial clinical hold on Ipsen’s palovarotene clinical trials in rare bone disorders in children less than 14 years old, due to bone growth concerns.
Freshly Funded ImCheck Goes After Gamma Delta T-Cells
ImCheck’s $53m series B financing will be used to develop antibodies that activate gamma delta T-cells for use against cancer and autoimmune diseases, its CEO tells Scrip.
Need a specific report? 1000+ reports available
Buy Reports